Kyverna Therapeutics

KYTX · NASDAQ

$6.04+$0.21 (+3.60%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $5.83

Latest news

Press releaseOct 7, 8:00 AM ETGlobe Newswire
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
NewsSep 24, 11:44 AM ETVandana Singh
Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions
Press releaseSep 24, 6:00 AM ETGlobe Newswire
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Press releaseAug 11, 4:02 PM ETGlobe Newswire
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Press releaseJun 22, 8:00 AM ETGlobe Newswire
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
Press releaseJun 3, 8:00 AM ETGlobe Newswire
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Press releaseMay 12, 4:02 PM ETGlobe Newswire
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
NewsApr 22, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsApr 22, 5:31 AM ETAvi Kapoor
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
NewsApr 22, 2:44 AM ETMohd Haider
Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?
Press releaseApr 21, 6:45 PM ETGlobe Newswire
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Press releaseApr 20, 8:00 AM ETGlobe Newswire
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
Press releaseApr 9, 8:00 AM ETGlobe Newswire
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
Press releaseMar 26, 4:02 PM ETGlobe Newswire
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
NewsDec 31, 10:01 AM ETNamrata Sen
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?
NewsDec 17, 12:02 PM ETAvi Kapoor
Crude Oil Rises Over 1%; General Mills Earnings Top Views
NewsDec 17, 9:39 AM ETAvi Kapoor
Dow Jumps 150 Points; Jabil Posts Upbeat Earnings
NewsDec 17, 8:04 AM ETAvi Kapoor
Lennar Posts Mixed Q4 Results, Joins Worthington Enterprises And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
NewsDec 15, 4:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsDec 15, 12:30 PM ETAvi Kapoor
Crude Oil Falls Over 1%; US Homebuilder Sentiment Edges Higher In December
NewsDec 15, 12:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsDec 15, 10:45 AM ETAvi Kapoor
Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday
NewsDec 15, 9:48 AM ETVandana Singh
Kyverna Stock Rockets After Cell Therapy Helps Patients Walk Again In Rare Disorder
NewsDec 15, 7:26 AM ET
Market-Moving News for December 15th
NewsDec 15, 4:54 AM ETAvi Kapoor
Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
NewsDec 4, 10:12 AM ETAvi Kapoor
Donaldson Posts Upbeat Results, Joins Science Applications International, Descartes Systems, Dollar General And Other Big Stocks Moving Higher On Thursday
NewsNov 20, 8:16 AM ETAvi Kapoor
Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Press releaseNov 12, 4:05 PM ETGlobe Newswire
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
NewsNov 4, 2:25 PM ETVandana Singh
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Press releaseOct 2, 7:17 AM ETGlobe Newswire
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NewsAug 20, 3:29 PM ETVandana Singh
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026
Press releaseJul 29, 8:30 AM ETPRNewswire
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise
NewsJul 15, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseJul 2, 9:00 PM ETGlobe Newswire
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Press releaseJun 30, 9:00 AM ETPRNewswire
Kyverna Therapeutics Announces Appointment of New Chief Financial Officer
Press releaseMay 28, 4:02 PM ETPRNewswire
Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference
NewsMay 27, 8:59 AM ETAvi Kapoor
This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Press releaseMay 15, 9:00 PM ETGlobe Newswire
KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Press releaseMay 13, 4:02 PM ETPRNewswire
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Press releaseMar 27, 4:02 PM ETPRNewswire
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Press releaseMar 17, 3:01 PM ETGlobe Newswire
Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf
Press releaseMar 13, 6:21 PM ETGlobe Newswire
Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf
Press releaseMar 3, 4:05 PM ETPRNewswire
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Press releaseFeb 7, 11:42 AM ETPRNewswire
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving?

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

Crude Oil Rises Over 1%; General Mills Earnings Top Views

Dow Jumps 150 Points; Jabil Posts Upbeat Earnings

Lennar Posts Mixed Q4 Results, Joins Worthington Enterprises And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Crude Oil Falls Over 1%; US Homebuilder Sentiment Edges Higher In December

12 Health Care Stocks Moving In Monday's Intraday Session

Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday

Kyverna Stock Rockets After Cell Therapy Helps Patients Walk Again In Rare Disorder

Market-Moving News for December 15th

Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

Donaldson Posts Upbeat Results, Joins Science Applications International, Descartes Systems, Dollar General And Other Big Stocks Moving Higher On Thursday

Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

12 Health Care Stocks Moving In Tuesday's Intraday Session

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Kyverna Therapeutics Announces Appointment of New Chief Financial Officer

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit